New obesity drug eloralintide enters early human testing

NCT ID NCT07665879

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This early-stage study tests whether a new drug, eloralintide, can improve how the body responds to insulin and manage weight in 115 adults with overweight or obesity. Participants will receive either the drug or a placebo injection and be monitored for about 35 weeks. The goal is to see if eloralintide can improve metabolic health, but because it is a Phase 1 trial, the main focus is on safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eloralintide (a drug injection)
What this could lead to: If it works, this could point toward a new treatment for obesity and related metabolic problems like insulin resistance.
What could go wrong: This is a very early Phase 1 trial with only 115 people, so it may not show clear benefits or could have side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

CTC GoCo
NOT_YET_RECRUITING

Mölndal, 431 53, Sweden
Profil Institut für Stoffwechselforschung
RECRUITING

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.